Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prolia in Glucocorticoid-induced Osteoporosis in Mainland China
NCT06588153Phase 4Active, not recruiting
- Sponsor
- Amgen
- Start
- May 2025
- Primary completion
- Apr 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of denosumab in glucocorticoid-induced osteoporosis (GIOP), sponsored by Amgen. Primary endpoint: Change from Baseline in Lumbar Spine Bone Mineral Density Percentage at 12 months. Started May 2025; status: active, not recruiting.
02
Drugs
denosumab
03
Conditions
glucocorticoid-induced osteoporosis (GIOP)
Beyond the preview
Go deeper on NCT06588153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06588153.